BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
News Medical on MSN3d
The role of FOXM1 and PD-L1 in malignant peripheral nerve sheath tumor resistanceA new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "Linking FOXM1 and PD-L1 to CDK4/6 ...
IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast CancerCasitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase ...
Casitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase that has been shown to be a key regulator of the activation of T and natural killer (NK) cells in the absence of CD28 costimulation GRC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback